XAn integrated overview of HIV-1 latency

Cell

Volumn 155, Issue 3, 2013, Pages 519-

  Ruelas, Debbie S ^a   Greene, Warner C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BRYOSTATIN; CYTOKINE; DNA; HISTONE ACETYLTRANSFERASE; RALTEGRAVIR; RNA POLYMERASE II; TRANSCRIPTION FACTOR; VALPROIC ACID; VIRUS DNA; VIRUS RNA; VORINOSTAT;

CD4+ T LYMPHOCYTE; CHROMATIN STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA METHYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOLOGICAL MEMORY; LIFE CYCLE; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROVIRUS; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; VIREMIA; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84886782112     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2013.09.044     Document Type: Review

References (101)

1. K. Allers, G. Hütter, J. Hofmann, C. Loddenkemper, K. Rieger, E. Thiel, and T. Schneider Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation Blood 117 2011 2791 2799
2. N.M. Archin, A. Espeseth, D. Parker, M. Cheema, D. Hazuda, and D.M. Margolis Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid AIDS Res. Hum. Retroviruses 25 2009 207 212
3. C. Banerjee, N. Archin, D. Michaels, A.C. Belkina, G.V. Denis, J. Bradner, P. Sebastiani, D.M. Margolis, and M. Montano BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 J. Leukoc. Biol. 92 2012 1147 1154
4. M. Barboric, R.M. Nissen, S. Kanazawa, N. Jabrane-Ferrat, and B.M. Peterlin NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II Mol. Cell 8 2001 327 337
5. F. Barré-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, and C. Rouzioux Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 1983 868 871
6. K. Bartholomeeusen, Y. Xiang, K. Fujinaga, and B.M. Peterlin Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein J. Biol. Chem. 287 2012 36609 36616
7. D.P. Bednarik, C. Duckett, S.U. Kim, V.L. Perez, K. Griffis, P.C. Guenthner, and T.M. Folks DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV-1 long terminal repeat cognate DNA motifs New Biol. 3 1991 969 976
8. J. Blazkova, K. Trejbalova, F. Gondois-Rey, P. Halfon, P. Philibert, A. Guiguen, E. Verdin, D. Olive, C. Van Lint, J. Hejnar, and I. Hirsch CpG methylation controls reactivation of HIV from latency PLoS Pathog. 5 2009 e1000554
9. J. Blazkova, D. Murray, J.S. Justement, E.K. Funk, A.K. Nelson, S. Moir, T.W. Chun, and A.S. Fauci Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy J. Virol. 86 2012 5390 5392
10. D. Boehm, V. Calvanese, R.D. Dar, S. Xing, S. Schroeder, L. Martins, K. Aull, P.C. Li, V. Planelles, and J.E. Bradner BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism Cell Cycle 12 2013 452 462
11. D.G. Brooks, D.H. Hamer, P.A. Arlen, L. Gao, G. Bristol, C.M. Kitchen, E.A. Berger, and J.A. Zack Molecular characterization, reactivation, and depletion of latent HIV Immunity 19 2003 413 423
12. M.J. Buzón, M. Massanella, J.M. Llibre, A. Esteve, V. Dahl, M.C. Puertas, J.M. Gatell, P. Domingo, R. Paredes, and M. Sharkey HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects Nat. Med. 16 2010 460 465
13. P. Cherepanov, G. Maertens, P. Proost, B. Devreese, J. Van Beeumen, Y. Engelborghs, E. De Clercq, and Z. Debyser HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells J. Biol. Chem. 278 2003 372 381
14. N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, B. Yassine-Diab, G. Boucher, M.R. Boulassel, G. Ghattas, and J.M. Brenchley HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation Nat. Med. 15 2009 893 900
15. S.K. Choudhary, N.M. Archin, and D.M. Margolis Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells J. Infect. Dis. 197 2008 1162 1170
16. T.W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R.F. Siliciano In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency Nat. Med. 1 1995 1284 1290
17. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, M. Baseler, A.L. Lloyd, M.A. Nowak, and A.S. Fauci Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc. Natl. Acad. Sci. USA 94 1997 13193 13197
18. T.W. Chun, D. Engel, M.M. Berrey, T. Shea, L. Corey, and A.S. Fauci Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection Proc. Natl. Acad. Sci. USA 95 1998 8869 8873
19. T.W. Chun, D. Engel, S.B. Mizell, L.A. Ehler, and A.S. Fauci Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines J. Exp. Med. 188 1998 83 91
20. T.W. Chun, D.C. Nickle, J.S. Justement, J.H. Meyers, G. Roby, C.W. Hallahan, S. Kottilil, S. Moir, J.M. Mican, and J.I. Mullins Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy J. Infect. Dis. 197 2008 714 720
21. C.M. Coleman, and L. Wu HIV interactions with monocytes and dendritic cells: viral latency and reservoirs Retrovirology 6 2009 51
22. X. Contreras, M. Barboric, T. Lenasi, and B.M. Peterlin HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription PLoS Pathog. 3 2007 1459 1469
23. R.Q. Cron, S.R. Bartz, A. Clausell, S.J. Bort, S.J. Klebanoff, and D.B. Lewis NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells Clin. Immunol. 94 2000 179 191
24. J.B. Dinoso, S.Y. Kim, A.M. Wiegand, S.E. Palmer, S.J. Gange, L. Cranmer, A. O'Shea, M. Callender, A. Spivak, and T. Brennan Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy Proc. Natl. Acad. Sci. USA 106 2009 9403 9408
25. G. Dornadula, H. Zhang, B. VanUitert, J. Stern, L. Livornese Jr., M.J. Ingerman, J. Witek, R.J. Kedanis, J. Natkin, and J. DeSimone Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy J. Am. Med. Assoc.: the journal of the American Medical Association 282 1999 1627 1632
26. M. Dybul, B. Hidalgo, T.W. Chun, M. Belson, S.A. Migueles, J.S. Justement, B. Herpin, C. Perry, C.W. Hallahan, and R.T. Davey Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection J. Infect. Dis. 185 2002 61 68
27. T.H. Evering, S. Mehandru, P. Racz, K. Tenner-Racz, M.A. Poles, A. Figueroa, H. Mohri, and M. Markowitz Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection PLoS Pathog. 8 2012 e1002506
28. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, T.C. Quinn, K. Chadwick, J. Margolick, and R. Brookmeyer Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
29. A.E. Friedman-Kien Disseminated Kaposi's sarcoma syndrome in young homosexual men J. Am. Acad. Dermatol. 5 1981 468 471
30. K. Fujinaga, D. Irwin, Y. Huang, R. Taube, T. Kurosu, and B.M. Peterlin Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element Mol. Cell. Biol. 24 2004 787 795
31. R.C. Gallo, S.Z. Salahuddin, M. Popovic, G.M. Shearer, M. Kaplan, B.F. Haynes, T.J. Palker, R. Redfield, J. Oleske, and B. Safai Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS Science 224 1984 500 503
32. R.T. Gandhi, L. Zheng, R.J. Bosch, E.S. Chan, D.M. Margolis, S. Read, B. Kallungal, S. Palmer, K. Medvik, M.M. Lederman AIDS Clinical Trials Group A5244 team The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial PLoS Med. 7 2010 7
33. C. García-Rodríguez, and A. Rao Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP) J. Exp. Med. 187 1998 2031 2036
34. K.B. Glaser, M.J. Staver, J.F. Waring, J. Stender, R.G. Ulrich, and S.K. Davidsen Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2 2003 151 163
35. M.S. Gottlieb, R. Schroff, H.M. Schanker, J.D. Weisman, P.T. Fan, R.A. Wolf, and A. Saxon Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency N. Engl. J. Med. 305 1981 1425 1431
36. G. Gras, and M. Kaul Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection Retrovirology 7 2010 30
37. I.H. Greger, F. Demarchi, M. Giacca, and N.J. Proudfoot Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter Nucleic Acids Res. 26 1998 1294 1301
38. Y. Han, K. Lassen, D. Monie, A.R. Sedaghat, S. Shimoji, X. Liu, T.C. Pierson, J.B. Margolick, R.F. Siliciano, and J.D. Siliciano Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes J. Virol. 78 2004 6122 6133
39. G. He, and D.M. Margolis Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat Mol. Cell. Biol. 22 2002 2965 2973
40. N. He, A.C. Pezda, and Q. Zhou Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation Mol. Cell. Biol. 26 2006 7068 7076
41. M. Hezareh, M.A. Moukil, I. Szanto, M. Pondarzewski, S. Mouche, N. Cherix, S.J. Brown, J.L. Carpentier, and M. Foti Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms Antivir. Chem. Chemother. 15 2004 207 222
42. D.D. Ho, T.R. Rota, and M.S. Hirsch Infection of monocyte/macrophages by human T lymphotropic virus type III J. Clin. Invest. 77 1986 1712 1715
43. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
44. Y.-C. Ho, L. Shan, N.N. Hosmane, J. Wang, S.B. Laskey, D.I.S. Rosenbloom, J. Lai, J.N. Blankson, J.D. Siliciano, and R.F. Siliciano Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure Cell 155 2013 540 551 this issue
45. W.Y. Hu, F.D. Bushman, and A.C. Siva RNA interference against retroviruses Virus Res. 102 2004 59 64
46. D. Ivanov, Y.T. Kwak, J. Guo, and R.B. Gaynor Domains in the SPT5 protein that modulate its transcriptional regulatory properties Mol. Cell. Biol. 20 2000 2970 2983
47. G. Jiang, A. Espeseth, D.J. Hazuda, and D.M. Margolis c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter J. Virol. 81 2007 10914 10923
48. K. Kaehlcke, A. Dorr, C. Hetzer-Egger, V. Kiermer, P. Henklein, M. Schnoelzer, E. Loret, P.A. Cole, E. Verdin, and M. Ott Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation Mol. Cell 12 2003 167 176
49. S.Y. Kao, A.F. Calman, P.A. Luciw, and B.M. Peterlin Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product Nature 330 1987 489 493
50. S.E. Kauder, A. Bosque, A. Lindqvist, V. Planelles, and E. Verdin Epigenetic regulation of HIV-1 latency by cytosine methylation PLoS Pathog. 5 2009 e1000495
51. K.S. Keedy, N.M. Archin, A.T. Gates, A. Espeseth, D.J. Hazuda, and D.M. Margolis A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression J. Virol. 83 2009 4749 4756
52. T.L. Kieffer, M.M. Finucane, R.E. Nettles, T.C. Quinn, K.W. Broman, S.C. Ray, D. Persaud, and R.F. Siliciano Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads J. Infect. Dis. 189 2004 1452 1465
53. Y.K. Kim, C.F. Bourgeois, C. Isel, M.J. Churcher, and J. Karn Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation Mol. Cell. Biol. 22 2002 4622 4637
54. Y.K. Kim, C.F. Bourgeois, R. Pearson, M. Tyagi, M.J. West, J. Wong, S.Y. Wu, C.M. Chiang, and J. Karn Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency EMBO J. 25 2006 3596 3604
55. Y.K. Kim, U. Mbonye, J. Hokello, and J. Karn T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway J. Mol. Biol. 410 2011 896 916
56. S. Kinoshita, B.K. Chen, H. Kaneshima, and G.P. Nolan Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells Cell 95 1998 595 604
57. A. Lafeuillade, C. Poggi, S. Chadapaud, G. Hittinger, M. Chouraqui, M. Pisapia, and E. Delbeke Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission J. Acquir. Immune Defic. Syndr. 26 2001 44 55
58. G. Lehrman, I.B. Hogue, S. Palmer, C. Jennings, C.A. Spina, A. Wiegand, A.L. Landay, R.W. Coombs, D.D. Richman, and J.W. Mellors Depletion of latent HIV-1 infection in vivo: a proof-of-concept study Lancet 366 2005 549 555
59. T. Lenasi, X. Contreras, and B.M. Peterlin Transcriptional interference antagonizes proviral gene expression to promote HIV latency Cell Host Microbe 4 2008 123 133
60. M.K. Lewinski, D. Bisgrove, P. Shinn, H. Chen, C. Hoffmann, S. Hannenhalli, E. Verdin, C.C. Berry, J.R. Ecker, and F.D. Bushman Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription J. Virol. 79 2005 6610 6619
61. M.K. Lewinski, M. Yamashita, M. Emerman, A. Ciuffi, H. Marshall, G. Crawford, F. Collins, P. Shinn, J. Leipzig, and S. Hannenhalli Retroviral DNA integration: viral and cellular determinants of target-site selection PLoS Pathog. 2 2006 e60
62. Z. Li, J. Guo, Y. Wu, and Q. Zhou The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation Nucleic Acids Res. 41 2013 277 287
63. K.V. Morris, S.W. Chan, S.E. Jacobsen, and D.J. Looney Small interfering RNA-induced transcriptional gene silencing in human cells Science 305 2004 1289 1292
64. S. Mujtaba, Y. He, L. Zeng, A. Farooq, J.E. Carlson, M. Ott, E. Verdin, and M.M. Zhou Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain Mol. Cell 9 2002 575 586
65. R.E. Nettles, T.L. Kieffer, P. Kwon, D. Monie, Y. Han, T. Parsons, J. Cofrancesco Jr., J.E. Gallant, T.C. Quinn, and B. Jackson Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART J. Am. Med. Assoc.: the journal of the American Medical Association 293 2005 817 829
66. M. Otero, G. Nunnari, D. Leto, J. Sullivan, F.X. Wang, I. Frank, Y. Xu, C. Patel, G. Dornadula, J. Kulkosky, and R.J. Pomerantz Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART AIDS Res. Hum. Retroviruses 19 2003 1097 1103
67. M. Ott, A. Dorr, C. Hetzer-Egger, K. Kaehlcke, M. Schnolzer, P. Henklein, P. Cole, M.M. Zhou, and E. Verdin Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation Novartis Foundation symposium 259 2004 182 193 discussion 193-186, 223-185
68. S. Pagans, A. Pedal, B.J. North, K. Kaehlcke, B.L. Marshall, A. Dorr, C. Hetzer-Egger, P. Henklein, R. Frye, and M.W. McBurney SIRT1 regulates HIV transcription via Tat deacetylation PLoS Biol. 3 2005 e41
69. A.S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D.D. Ho Decay characteristics of HIV-1-infected compartments during combination therapy Nature 387 1997 188 191
70. M. Pérez, A.G. de Vinuesa, G. Sanchez-Duffhues, N. Marquez, M.L. Bellido, M.A. Muñoz-Fernandez, S. Moreno, T.P. Castor, M.A. Calzado, and E. Muñoz Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency Curr. HIV Res. 8 2010 418 429
71. N.D. Perkins, N.L. Edwards, C.S. Duckett, A.B. Agranoff, R.M. Schmid, and G.J. Nabel A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation EMBO J. 12 1993 3551 3558
72. S. Popov, A.L. Chenine, A. Gruber, P.L. Li, and R.M. Ruprecht Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells J. Virol. 79 2005 602 608
73. M. Popovic, M.G. Sarngadharan, E. Read, and R.C. Gallo Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS Science 224 1984 497 500
74. S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J.S. Gatot, V. Quivy, C. Vanhulle, A. Lamine, D. Vaira, and D. Demonte Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection PLoS ONE 4 2009 e6093
75. A. Sáez-Cirión, C. Bacchus, L. Hocqueloux, V. Avettand-Fenoel, I. Girault, C. Lecuroux, V. Potard, P. Versmisse, A. Melard, T. Prazuck ANRS VISCONTI Study Group Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study PLoS Pathog. 9 2013 e1003211
76. N. Sagot-Lerolle, A. Lamine, M.L. Chaix, F. Boufassa, J.P. Aboulker, D. Costagliola, C. Goujard, C. Pallier, J.F. Delfraissy, O. Lambotte ANRS EP39 study Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir AIDS 22 2008 1125 1129
77. M.G. Sarngadharan, M. Popovic, L. Bruch, J. Schüpbach, and R.C. Gallo Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS Science 224 1984 506 508
78. L.J. Scherer, and J.J. Rossi Approaches for the sequence-specific knockdown of mRNA Nat. Biotechnol. 21 2003 1457 1465
79. A.R. Schröder, P. Shinn, H. Chen, C. Berry, J.R. Ecker, and F. Bushman HIV-1 integration in the human genome favors active genes and local hotspots Cell 110 2002 521 529
80. J. Schüpbach, M. Popovic, R.V. Gilden, M.A. Gonda, M.G. Sarngadharan, and R.C. Gallo Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS Science 224 1984 503 505
81. L. Shan, K. Deng, N.S. Shroff, C.M. Durand, S.A. Rabi, H.C. Yang, H. Zhang, J.B. Margolick, J.N. Blankson, and R.F. Siliciano Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation Immunity 36 2012 491 501
82. K. Shortman, and S.H. Naik Steady-state and inflammatory dendritic-cell development Nat. Rev. Immunol. 7 2007 19 30
83. F.P. Siegal, C. Lopez, G.S. Hammer, A.E. Brown, S.J. Kornfeld, J. Gold, J. Hassett, S.Z. Hirschman, C. Cunningham-Rundles, and B.R. Adelsberg Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions N. Engl. J. Med. 305 1981 1439 1444
84. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, J.B. Margolick, C. Kovacs, S.J. Gange, and R.F. Siliciano Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat. Med. 9 2003 727 728
85. J.D. Siliciano, J. Lai, M. Callender, E. Pitt, H. Zhang, J.B. Margolick, J.E. Gallant, J. Cofrancesco Jr., R.D. Moore, S.J. Gange, and R.F. Siliciano Stability of the latent reservoir for HIV-1 in patients receiving valproic acid J. Infect. Dis. 195 2007 833 836
86. B.A. Smith, S. Gartner, Y. Liu, A.S. Perelson, N.I. Stilianakis, B.F. Keele, T.M. Kerkering, A. Ferreira-Gonzalez, A.K. Szakal, J.G. Tew, and G.F. Burton Persistence of infectious HIV on follicular dendritic cells J. Immunol. 166 2001 690 696
87. H.J. Stellbrink, J. van Lunzen, M. Westby, E. O'Sullivan, C. Schneider, A. Adam, L. Weitner, B. Kuhlmann, C. Hoffmann, and S. Fenske Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial) AIDS 16 2002 1479 1487
88. M. Tyagi, and J. Karn CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency EMBO J. 26 2007 4985 4995
89. C. Van Lint, S. Emiliani, M. Ott, and E. Verdin Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation EMBO J. 15 1996 1112 1120
90. R.M. van Praag, J.M. Prins, M.T. Roos, P.T. Schellekens, I.J. Ten Berge, S.L. Yong, H. Schuitemaker, A.J. Eerenberg, S. Jurriaans, and F. de Wolf OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion J. Clin. Immunol. 21 2001 218 226
91. E. Verdin, P. Paras Jr., and C. Van Lint Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation EMBO J. 12 1993 3249 3259
92. X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, and B.H. Hahn Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122
93. P. Wei, M.E. Garber, S.M. Fang, W.H. Fischer, and K.A. Jones A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA Cell 92 1998 451 462
94. L.S. Weinberger, J.C. Burnett, J.E. Toettcher, A.P. Arkin, and D.V. Schaffer Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity Cell 122 2005 169 182
95. S.A. Williams, L.F. Chen, H. Kwon, D. Fenard, D. Bisgrove, E. Verdin, and W.C. Greene Prostratin antagonizes HIV latency by activating NF-kappaB J. Biol. Chem. 279 2004 42008 42017
96. S.A. Williams, L.F. Chen, H. Kwon, C.M. Ruiz-Jarabo, E. Verdin, and W.C. Greene NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation EMBO J. 25 2006 139 149
97. J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, and D.D. Richman Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295
98. Y. Yamaguchi, H. Shibata, and H. Handa Transcription elongation factors DSIF and NELF: promoter-proximal pausing and beyond Biochim. Biophys. Acta 1829 2013 98 104
99. J.H. Yik, R. Chen, R. Nishimura, J.L. Jennings, A.J. Link, and Q. Zhou Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA Mol. Cell 12 2003 971 982
100. S.A. Yukl, E. Boritz, M. Busch, C. Bentsen, T.W. Chun, D. Douek, E. Eisele, A. Haase, Y.C. Ho, and G. Hütter Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient PLoS Pathog. 9 2013 e1003347
101. H. Zhong, M.J. May, E. Jimi, and S. Ghosh The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1 Mol. Cell 9 2002 625 636